Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Infant, Premature, Diseases D007235 7 associated lipids
Infertility, Male D007248 11 associated lipids
Inflammation D007249 119 associated lipids
Intestinal Obstruction D007415 6 associated lipids
Ischemia D007511 18 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Klebsiella Infections D007710 7 associated lipids
Leukemia D007938 74 associated lipids
Leukemia, Experimental D007942 42 associated lipids
Leukopenia D007970 9 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Liver Cirrhosis, Experimental D008106 36 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lupus Nephritis D008181 8 associated lipids
Lymphoma D008223 18 associated lipids
Malabsorption Syndromes D008286 16 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Medulloblastoma D008527 22 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Mueller HW et al. 1-O-alkyl-linked glycerophospholipids of human neutrophils: distribution of arachidonate and other acyl residues in the ether-linked and diacyl species. 1984 J. Lipid Res. pmid:6427378
Mendlovic F et al. Possible involvement of cyclooxygenase products in the actions of platelet-activating factor and of lipoxygenase products in the vascular effects of epinephrine in perfused rat liver. 1984 Biochem. Biophys. Res. Commun. pmid:6435614
Fouque F and Vargaftig BB Triggering by Paf-acether and adrenaline of cyclo-oxygenase-independent platelet aggregation. 1984 Br. J. Pharmacol. pmid:6439269
Karlsson G and Pipkorn U Effect of disodium chromoglycate on changes in nasal airway resistance induced by platelet activating factor. 1984 Eur. J. Clin. Pharmacol. pmid:6439565
Sänze JU et al. On the nature of the vasoreactivity depressing factor (VDF) in inflammation and anaphylaxis in the rat and mouse. 1984 Biomed. Biochim. Acta pmid:6440544
Handley DA et al. Effect of platelet activating factor on endothelial permeability to plasma macromolecules. 1984 Immunopharmacology pmid:6083990
Camussi G et al. Effect of platelet activating factor on guinea-pig papillary muscle. 1984 Experientia pmid:6086382
Sills RH Thrombotic thrombocytopenic purpura. I. Pathophysiology and clinical manifestations. 1984 Am J Pediatr Hematol Oncol pmid:6442830
Lartigue-Mattei C et al. Pharmacokinetic study of 3H-labelled PAF-acether II. Comparison with 3H-labelled lyso-PAF-acether after intravenous administration in the rabbit and protein binding. 1984 Agents Actions pmid:6532184
Kulikov VI et al. [Incorporation of 1-0-alkyl-2-acetyl-sn-glycerol-3-phosphocholine into human plasma lipoproteins in vitro. Effect of the lecithin:cholesterol acyltransferase activity of plasma]. 1984 Biokhimiia pmid:6542803
Nagata K et al. [Thrombotic thrombocytopenic purpura (TTP) with a remission following splenectomy after the failure of antiplatelet therapy and plasmapheresis]. 1984 Rinsho Ketsueki pmid:6542941
Pirotzky E et al. PAF-acether-induced plasma exudation in rat skin is independent of platelets and neutrophils. 1984 Microcirc Endothelium Lymphatics pmid:6546141
Smith RJ et al. Stimulation of the human neutrophil superoxide anion-generating system with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3- phosphorylcholine. 1984 Biochem. Pharmacol. pmid:6324816
Buxton DB et al. Stimulation of hepatic glycogenolysis by acetylglyceryl ether phosphorylcholine. 1984 J. Biol. Chem. pmid:6693418
Sakamoto H et al. Stimulation of leukocyte phagocytic activity by the platelet release reaction. 1984 Pathology pmid:6462776
Shukla SD and Hanahan DJ Acetylglyceryl ether phosphorylcholine (AGEPC; platelet-activating factor)-induced stimulation of rabbit platelets: correlation between phosphatidic acid level, 45Ca2+ uptake, and [3H]serotonin secretion. 1984 Arch. Biochem. Biophys. pmid:6465886
Doebber TW et al. Platelet activating factor intravenous infusion in rats stimulates vascular lysosomal hydrolase secretion independent of blood neutrophils. 1984 Biochem. Biophys. Res. Commun. pmid:6517949
Heinrich J and Zimmermann RE Compound 48/80 is a potent inhibitor of human platelet aggregation antagonizing the calmodulin-dependent platelet reaction in vitro. 1984 Thromb. Res. pmid:6523451
Oxholm P et al. Lack of evidence for human lymphokines with thrombocyte aggregating activity. An in vitro study. 1984 Allergy pmid:6528957
Hwang SB et al. Effects of nonsteroid antiinflammatory drugs on the specific binding of platelet activating factor to membrane preparations of rabbit platelets. 1984 Thromb. Res. pmid:6429890
Colditz IG and Movat HZ Kinetics of neutrophil accumulation in acute inflammatory lesions induced by chemotaxins and chemotaxinigens. 1984 J. Immunol. pmid:6470487
Patterson R et al. Airway responses to sequential challenges with platelet-activating factor and leukotriene D4 in rhesus monkeys. 1984 J. Lab. Clin. Med. pmid:6470563
Ludwig JC et al. Modulation of platelet-activating factor (PAF) synthesis and release from human polymorphonuclear leukocytes (PMN): role of extracellular Ca2+. 1984 Arch. Biochem. Biophys. pmid:6430234
Feuerstein G et al. Effect of platelet-activating factor on coronary circulation of the domestic pig. 1984 Am. J. Physiol. pmid:6703081
Pipkorn U et al. Effect of platelet activating factor on the human nasal mucosa. 1984 Allergy pmid:6703263
Lüthje J and Ogilvie A Diadenosine triphosphate (Ap3A) mediates human platelet aggregation by liberation of ADP. 1984 Biochem. Biophys. Res. Commun. pmid:6704102
Clare KA and Scrutton MC The role of Ca2+ uptake in the response of human platelets to adrenaline and to 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor). 1984 Eur. J. Biochem. pmid:6705791
Kumar R et al. A facile route to semi-synthesis of acetyl glycerylether phosphoethanolamine and its choline analogue. 1984 J. Lipid Res. pmid:6707528
Archer CB et al. Synergistic interaction between prostaglandins and PAF-acether in experimental animals and man. 1984 Prostaglandins pmid:6203139
Schlondorff D et al. Effect of platelet-activating factor and serum-treated zymosan on prostaglandin E2 synthesis, arachidonic acid release, and contraction of cultured rat mesangial cells. 1984 J. Clin. Invest. pmid:6423667
Vargaftig BB et al. [Platelet aggregation and PAF-acether. Pharmacologic interference]. 1984 J Pharmacol pmid:6374298
Ito S et al. Hyperacute renal allograft rejection in the rabbit. The role of platelet-activating factor and of cationic proteins derived from polymorphonuclear leukocytes and from platelets. 1984 Lab. Invest. pmid:6379289
Bult H et al. Complement derived factors and prostacyclin formation by rabbit isolated peritoneum and cultured mesothelial cells. 1984 Agents Actions Suppl. pmid:6382974
Hechtman HB et al. Role of humoral mediators in adult respiratory distress syndrome. 1984 Chest pmid:6383742
Kelton JG et al. The detection of a platelet-agglutinating factor in thrombotic thrombocytopenic purpura. 1984 Ann. Intern. Med. pmid:6333196
Bussolino F et al. Release of platelet-activating factor (PAF)-like material from human lymphoid cell lines. 1984 Exp. Hematol. pmid:6333353
Wodzinowska B and Krajewski T [Role of blood platelets and their membrane in the process of hemostasis]. 1984 Jan-Feb Postepy Hig Med Dosw pmid:6093087
Vemulapalli S et al. Cardiovascular and renal action of platelet-activating factor in anesthetized dogs. 1984 Jul-Aug Hypertension pmid:6378787
Cox CP et al. VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF). 1984 Mar-Apr Peptides pmid:6206481
Proll MA et al. Phosphatidate and monooleylphosphatidate inhibition of fibroblast adenylate cyclase is mediated by the inhibitory coupling protein, Ni. 1985 Mol. Pharmacol. pmid:2997592
Weber N and Benning H Ether glycerolipids: novel substrates for studying specificity of enzymes involved in glycerolipid biosynthesis in higher plants. 1985 Eur. J. Biochem. pmid:3967662
O'Neill C Partial characterization of the embryo-derived platelet-activating factor in mice. 1985 J. Reprod. Fertil. pmid:4067921
Mallet AI and Cunningham FM Structural identification of platelet activating factor in psoriatic scale. 1985 Biochem. Biophys. Res. Commun. pmid:3970690
Wissner A et al. Analogues of platelet activating factor. 3. Replacement of the phosphate moiety with a sulfonylbismethylene group. 1985 J. Med. Chem. pmid:4032438
MacIntyre DE et al. Tumour-promoting phorbol esters inhibit agonist-induced phosphatidate formation and Ca2+ flux in human platelets. 1985 FEBS Lett. pmid:2981715
Bergelson LD et al. Influence of platelet activation factor and prostaglandins on cholesterol esterification in human plasma. 1985 FEBS Lett. pmid:4043408
Kilpatrick JM and Virella G Inhibition of platelet-activating factor by rabbit C-reactive protein. 1985 Clin. Immunol. Immunopathol. pmid:4042435
O'Flaherty JT Neutrophil degranulation: evidence pertaining to its mediation by the combined effects of leukotriene B4, platelet-activating factor, and 5-HETE. 1985 J. Cell. Physiol. pmid:2981891
Khan SN et al. Desaggregation of PAF-acether-aggregated platelets by verapamil and TMB-8 with reversal of phosphorylation of 40K and 20K proteins. 1985 Eur. J. Pharmacol. pmid:3920056
Bushfield M et al. Inhibition of platelet-activating-factor-induced human platelet activation by prostaglandin D2. Differential sensitivity of platelet transduction processes and functional responses to inhibition by cyclic AMP. 1985 Biochem. J. pmid:3002327